beat top bottom line
guidanc light top bottom
line remain transit year convers
pipelin progress key driver
top-line bottom-lin beat revenu beat ep beat
beat driven soliri ultomiri
strensiq kanuma soliri revenu growth primarili
gmg off-set partial russia biosimilar guidanc management
introduc follow total revenu vs con
revenu vs con revenu vs
con sg revenu vs con oper margin
vs con non-gaap ep vs con non-gaap
takeaway call ultomiri pnh convers rate stand
us germani japan management also
comment convers pace ahu similar pnh earli
stage management clarifi top-line guidanc account follow
headwind given larg switch ultomiri management expect
headwind top-line attribut lower price per mainten
patient pnh ii lower price per patient ahu wherein cost
lower first year ultomiri vs soliri lower thereaft
howev management expect headwind partli off-set growth
neurolog indic soliri gmg nmo management note
bottom-lin guidanc take consider expens expect
increas given larg number on-going clinic studi ii
close transact achillion iii mileston management
potenti pay relat recent bd activ iv increas
tax rate management reiter goal
quadrupl neurolog patient us ii achiev launch
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
although management indic aspir goal guidanc
iii explor potenti bd opportun would diversifi pipelin management
indic number gmg nmosd patient treat soliri
fcrn program management clarifi
clinic trial healthi volunt commenc dec use higher
concentr subcutan administr phii studi hemolyt
anemia iv formul resum upon complet
trial management plan initi registr program late management also
comment gmg phii initi dose rang studi
potenti includ seamless phii/phii trial design
subcutan ultomiri phiii studi management announc enrol
complet management report data management reiter
iv formul ultimiri file us eu late
management plan file japan management announc
patent offic recent allow new patent applic soliri
applic provid addit patent protect
claim newli allow applic cover method
treat pnh soliri note though claim similar
claim alexion patent current challeng
ipr thu unclear robust new protect
updat mainli expect investor focu much room management may
back guidanc overal quarter gener expect
continu progress ultomiri convers neurolog indic
soliri management guidanc softer metabol forecast
in-line expect franchis ultim believ management
probabl conserv margin profil thu see
upsid ep strang way faster ahu convers actual drag
revenu thu believ management top-line guidanc overli
conserv look forward pipelin updat key driver
potenti inflect investor view
ultomiri convers soliri neurolog launch pipelin drive risk/reward
deriv pt discount cash ow analysi assum wacc
termin growth rate revenu driver model pnh sale ahu sale mg
sale nmo sale strensiq sale kanuma sale
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
ahu mg penetr ultomiri
ahu mg penetr ultomiri
succe signic share convers
succe signic share convers
standard care pnh ahu nmo
mg pnh sale
peak ww ahu sale
peak assum strensiq
kanuma continu launch
sale respect
soliri meaning growth pnh ahu
soliri meaning growth pnh ahu
gmg
gmg ultomiri succe modest
solid convers ultomiri long-term
durabl complement franchis
assum gmg nmo meaning
contribut sale assum strensiq
kanuma continu launch
sale respect
see soliri longev incorpor
competit price pressur
equal-weight believ
despit strong execut management consensu
need see greater revenu divers
away franchis
increas termin multipl
believ initi ultomiri execut
strong pnh expect similar
transit ahu see option
subcutan neurolog indic
expect potenti posit
develop pipelin believ
management undertak organ rebuild
compani take time drive new
view descript risk reward theme
kanuma achiev minim sale
kanuma achiev minim sale bear
case assum soliri fail gain label
expans soliri face signic
headwind biosimilar
proprietari competit divers
strensiq kanuma minim
initi phiii studi al ultomiri iv
start pivot phii/iii al amyloidosi
eido phiii data primari mitochondri myopathi pmm
init phii studi waiha iv
phi sad/mad data test high afniti protein ligand
administr pnh/ahu
ultomiri mg/ml launch pnh
view explan region hierarchi
research highest favor quintil
soliri pnh ahu mg growth could fail
meet expect
strensiq and/or kanuma fail captur market
share convers soliri ultomiri
project
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
